A Phase 2, Multi-center, Single-arm Study of TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Who Received at Least 2 Prior Lines of Treatment
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs MOR 202 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors I-MAB Biopharma
- 14 Oct 2019 According to an I-MAB Biopharma media release, the company has received Investigational New Drug (IND) clearances from the National Medical Products Administration (NMPA) of China to expand the ongoing trial also to mainland China.
- 19 Mar 2019 According to a MorphoSys media release, this study could lead to a biologics license application (BLA) in Greater China.
- 19 Mar 2019 According to a MorphoSys media release, first patient has been dosed in this study.